Beam Therapeutics Inc - ESG Rating & Company Profile powered by AI
Complete ESG analysis of Beam Therapeutics Inc can be reached by logging in. This dashboard includes a Q&A table on Beam Therapeutics Inc. This report of Beam Therapeutics Inc incorporates information from across the web and also from public disclosures by Beam Therapeutics Inc.
Beam Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 4.6, social score of 2.0 and governance score of 5.0.
3.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1443 | XSpray Pharma AB (publ) | 4.0 | High |
| 1443 | Zhong Yuan Bio-Technology Holdings Ltd | 4.0 | High |
| ... | ... | ... | |
| 1476 | Beam Therapeutics Inc | 3.9 | Medium |
| 1476 | Anebulo Pharmaceuticals Inc | 3.9 | Medium |
| 1476 | Anhui Sunhere Pharmaceutical Excipients Co Ltd | 3.9 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Beam Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Beam Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Beam Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Beam Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Beam Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Beam Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Beam Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Beam Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Beam Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Beam Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Beam Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Beam Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Beam Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Beam Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Beam Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Beam Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Beam Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Beam Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.